Who is sponsoring NCT07096206?

NCT07096206 is sponsored by Pierre Fabre Medicament.

What condition does NCT07096206 study?

NCT07096206 studies X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED).

Is NCT07096206 still recruiting?

NCT07096206 is currently active, enrolled. Last updated 31 July 2025.

Last reviewed 2025-07-31 · How we verify

NCT07096206: EdeReaLife

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International Study

Active, enrolled Last updated 31 July 2025

What this trial tests

trial in X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) in 27 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 July 2023

Primary endpoint
19 November 2026

19 November 2026

Quick facts

Lead sponsor	Pierre Fabre Medicament
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	27
Start date	19 July 2023
Primary completion	19 November 2026
Estimated completion	19 November 2026
Sites	2 locations across France, Germany

Conditions studied

X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) — all drugs for X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED) →

Sponsor

Pierre Fabre Medicament — full company profile →

Who can join

Adults 0 to 11, male only, with X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an observational, multicentre, international study over a 2-year follow-up period. The aim of this study is to understand how XLHED affects the lives of young male patients and their families over time. By studying the natural course of the disease and its impact, the study could improve the understanding of the challenges faced by these patients and their families.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Pierre Fabre Medicament trials

Trials by the same sponsor.

NCT06690489 — An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients · completed
NCT06669117 — FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations · Phase 1, PHASE2 · recruiting
NCT06688370 — The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study · terminated
NCT06043817 — First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H · Phase 1, PHASE2 · recruiting
NCT06623773 — Study on Structum® in Adult Patients With Osteoarthritis (TRUST) · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07096206 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Medicament
Last refreshed: 31 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07096206.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing